Proteasome inhibitor induced RIPK 3-dependent cell death 1 Regulation of RIPK 3 and RHIM-dependent necroptosis by the proteasome
Kenta Moriwaki,Francis Ka-Ming Chan
2016-01-01
Abstract:Receptor interacting protein kinase 3 (RIPK3) is a serine/threonine kinase with essential function in necroptosis. The activity of RIPK3 is controlled by phosphorylation. Once activated, RIPK3 phosphorylates and activates the downstream effector mixed lineage kinase domain-like (MLKL) to induce necroptosis. In certain situations, RIPK3 has also been shown to promote apoptosis or cytokine expression in a necroptosis and kinase-independent manner. The ubiquitinproteasome system is the major pathway for selective degradation of cellular proteins and thus has a critical role in many cellular processes such as cell survival and cell death. Clinically, proteasome inhibition has shown promise as an anti-cancer agent. Here we show that the proteasome inhibitors MG132 and bortezomib activate the RIPK3-MLKL necroptotic pathway in mouse fibroblasts as well as human leukemia cells. Unlike necroptosis induced by classical TNF-like cytokines, necroptosis induced by proteasome inhibitors does not require caspase inhibition. However, an intact RIP homotypic interaction motif (RHIM) is essential. Surprisingly, when recruitment of MLKL to RIPK3 is restricted, proteasome inhibitors induced RIPK3-dependent apoptosis. Proteasome inhibition led to accumulation of K48-linked ubiquitinated RIPK3, which was partially reduced when K264 was mutated. Taken together, these results reveal the ubiquitin-proteasome system as a novel regulatory mechanism for RIPK3-dependent necroptosis. INTRODUCTION Tissue homeostasis is maintained through dynamic balance between cell survival and cell death. A number of diseases such as cancer can be attributed to perturbation of this balance. Caspasedependent apoptosis is a key cell death module with important functions in development and certain disease pathologies. In addition to apoptosis, recent evidence shows that a form of regulated necrosis, termed necroptosis, is significantly associated with a number of common clinical diseases such as viral infection, ischemiareperfusion injury, myocardial infarction, atherosclerosis, and inflammatory bowel diseases (1,2). Necroptosis is driven by the cytosolic serine/threonine kinase receptor-interacting protein kinase 3 (RIPK3) (3). A wide variety of stimuli including tumor necrosis factor (TNF) superfamily death ligands have been reported to induce necroptosis (1). Ligation of TNF to TNF receptor (TNFR) 1 causes formation of receptorassociated Complex I, which comprises of TNFR1-associated via death domain (TRADD), TNFR-associated factor 2 (TRAF2), cellular inhibitor of apoptosis 1 (cIAP1), cIAP2, linear ubiquitin chain assembly complex (LUBAC), and RIPK1. cIAPs and LUBAC promotes RIPK1 ubiquitination through K11, K63 and linear ubiquitin linkages, which promotes activation of NF-B and cell survival in part by limiting the formation of the cytosolic death-inducing signaling complex (DISC, aka complex IIa). Removal of the ubiquitin chains on RIPK1 by the http://www.jbc.org/cgi/doi/10.1074/jbc.M115.700997 The latest version is at JBC Papers in Press. Published on January 19, 2016 as Manuscript M115.700997 Copyright 2016 by The American Society for Biochemistry and Molecular Biology, Inc. by gest on Feruary 4, 2016 hp://w w w .jb.org/ D ow nladed from Proteasome inhibitor induced RIPK3-dependent cell death 2 de-ubiquitinase cylindromatosis (CYLD) promotes Complex IIa formation and apoptosis (4). When caspase 8 activity is blocked, RIPK3 is recruited to the complex to promote necroptosis. Besides RIPK1 and RIPK3, caspase 8 and its adaptor Fasassociated via death domain (FADD) are also major components of Complex IIa and the RIPK3associated Complex IIb (aka the necrosome). RIPK3 possesses an active kinase domain in the N-terminus and a unique protein-protein interaction domain called the RIP homotypic interaction motif (RHIM) at the C-terminus (5). Phosphorylation of RIPK1 and RIPK3 in their kinase domains facilitates RHIM-mediated interaction between RIPK1 and RIPK3 and formation of an amyloid-like filamentous signaling complex (6,7). Although RIPK1 is required for TNF-induced RIPK3 activation, it is not a prerequisite in toll like receptor 3 (TLR3) or interferon-induced necroptosis (8). Phosphorylation of RIPK3 at T231/S232 (S232 in human RIPK3) stimulates recruitment and phosphorylation of the downstream substrate mixed lineage kinase-domain like (MLKL). Activated MLKL undergoes oligomerization and translocates to intracellular and plasma membranes, which eventually leads to membrane lesions through a yet-to-be-defined mechanism (915). The proteasome is a large multimeric complex responsible for selective degradation of proteins that are covalently modified by K48or K11-linked polyubiquitin chains (16). The expression of many proteins with important functions in cell cycle or cell death is often controlled by the ubiquitin-proteasome system (UPS). As a result, defects in proteasomal degradation can lead to various disorders (17). In cancers, targeting the UPS has proved to be an effective therapeutic approach (18). For example, a first-in-class proteasome inhibitor, bortezomib, has been successfully used for treatment of multiple myeloma and mantle cell lymphoma (19). The success of bortezomib has led to efforts to develop second-generation proteasome inhibitors with improved safety and efficiency (20). Despite the importance of the UPS in biology, relatively little is known about its role in necroptosis. Here, we show that proteasome inhibitors can potently induce RIPK3-dependent necroptosis. Proteasome inhibitor-induced necroptosis requires an intact RHIM in RIPK3 and downstream activation of MLKL. Surprisingly, when recruitment of or access to MLKL is impeded, proteasome inhibitors promote RIPK3dependent apoptosis instead. Mechanistically, proteasome inhibitors triggered the accumulation of K48-linked ubiquitinated RIPK3. Mutation of K264 in the kinase domain of RIPK3 significantly reduced proteasome-induced RIPK3 ubiquitination and necroptosis. These results reveal an important function of the UPS in the regulation of necroptosis and suggest that targeting this pathway may be a useful strategy in cancer therapy. EXPERIMENTAL PROCEDURES Reagents – z-VAD-fmk, z-IETD-fmk, MG132, staurosporine, and necrostatin-1 were obtained from Enzo Lifesciences. Doxycycline, cycloheximide, 5-FU, oxaliplatin, irinotecan, doxorubicin, and etoposide were obtained from Sigma. Bortezomib was obtained from ApexBio. Anti-mouse Fas agonistic Jo2 antibody was obtained from BD Biosciences. Anti-human Fas agonistic CH11 antibody was obtained from Millipore. Anti-mouse TNF blocking antibody was obtained from R&D systems. GSK’840 and GSK’843 were kindly provided by J. Bertin and P. Gough. BV6 was kindly provided by D. Vucic. Cell Culture – Ripk3 -/3T3, Ripk1 -/3T3, and 293T cells were cultured in DMEM media. T cell leukemia cell lines Jurkat and H9 were cultured in RPMI media. Ten percent fetal calf serum, 2 mM glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin were added to the media. Plasmids, Viruses, Transfections, and Transductions – Wild type mouse Ripk3 genes were cloned into a modified lentiviral tet-on pTRIPZ/Puro vector. Wild type mouse Ripk3 and Mlkl genes were also cloned into a retroviral pMSCV/Hyg vector. HA and FLAG tags were introduced at the amino and carboxyl termini of RIPK3 by PCR cloning, respectively. FLAG tag was fused at the amino terminus of MLKL. Each mutant Ripk3 expression vector was generated by site-directed mutagenesis. For RHIM mutant, the tetra core sequence of RHIM, VQIG, of mouse by gest on Feruary 4, 2016 hp://w w w .jb.org/ D ow nladed from Proteasome inhibitor induced RIPK3-dependent cell death 3 RIPK3, was mutated to AAAA. The sequence of all the genes inserted was confirmed by sequence analysis. pGIPZ/puro vector carrying shRNA against mouse Mlkl (Open Biosystems, V3LMM_485516) was used to silence MLKL expression. pGIPZ vector carrying non-silencing scrambled shRNA was used as negative control (Open Biosystems, RHS4346). Lentivirus was generated by transfecting the virus vectors into 293T cells with pMD2.G and psPAX2 vectors. After 24 hours, culture media were replaced and the cells were further cultured for 24 hours. Retrovirus was generated by transfection in 293T cells using VSV-G and Gag/Pol packaging vectors. Culture media were collected, filtered, and used for transduction with 10 g/ml polybrene. After transduction, the cells were selected by hygromycin B (300 g/ml) or puromycin (2 g/ml). RIPK3 expression was induced by 1 g/ml doxycycline. Western blot and Immunoprecipitation (IP) – Whole cell extracts were prepared in RIPA lysis buffer and resolved on 4-20% polyacrylamide gels from Invitrogen or GenScript. To detect MLKL oligomers, lysates were heated at 70 o C for 10 minutes in SDS loading buffer without DTT. After transferring proteins to nitrocellulose membrane, immunoblot analysis was performed with the following antibodies: Anti-mouse RIPK3 (2283, Prosci), human RIPK3 (generated in our own lab), mouse RIPK1 (38/RIP, BD Biosciences), mouse caspase 8 (1G12, Enzo Lifesciences), human caspase 8 (12F5, Enzo Lifesciences), human cleaved PARP (9541, Cell Signaling Technology), mouse caspase 3 (46, Santa Cruz), human/mouse MLKL (3H1, Millipore), phospho human MLKL (EPR9514, Abcam), human/mouse cIAP1 (AF818, R&D Systems), ubiquitin (Ubi-1, Sigma), K48 ubiquitin (Apu2, Millipore), K63 ubiquitin (Apu3, Millipore), and mouse FADD (kindly provided by A. Winoto at the University of California, Berkeley) antibodies. Anti--actin (3779, Prosci) and HSP90 (68/Hsp90, BD Biosciences) antibodies were used as loading controls. For IP, RIPA lysates were pre-cleared by sepharose 6B (Sigma) for 1 hour at 4 o C, followed by incubation with anti-mouse RIPK3 antibody and anti-rabbit IgG conjugated agarose beads (Sigma) at 4 o C overnight. After washes in RIPA buffer (5X), the resulting immune complex was resolved on polyacrylamide gel. For denatu